IFRS 9 ECL Assets: Stage 1 Curing Criteria

Welcome back to the Lux Actuaries blog! Today, we're diving into a specific, yet crucial, aspect of IFRS 9 Expected Credit Loss (ECL): how an asset can transition from Stage 2 back to Stage 1. While much attention is given to identifying when credit risk has significantly increased (pushing an asset into Stage 2), understanding the criteria for its 'curing' – or moving it back – is equally vital for accurate financial reporting and risk management.

Under IFRS 9, assets are categorised into three stages based on their credit risk. Stage 1 represents assets with no significant increase in credit risk since initial recognition, where we calculate 12-month ECL. Stage 2 includes assets that have experienced a Significant Increase in Credit Risk (SICR) since initial recognition, requiring lifetime ECL. Stage 3 involves assets that are credit-impaired, also requiring lifetime ECL and specific interest income recognition.

The natural question then arises: if an asset's credit risk has improved, can it return to Stage 1? Absolutely! However, this isn't a mere reversal. It requires robust, evidence-based criteria to demonstrate that the significant increase in credit risk that initially moved the asset into Stage 2 no longer exists. This is where 'curing criteria' come into play.

The Core Principle: No More SICR

At its heart, the primary condition for an asset to transition from Stage 2 back to Stage 1 is that there must no longer be a Significant Increase in Credit Risk (SICR) since its initial recognition. This means the current credit risk profile of the asset must be comparable to, or even better than, when it was first recognised, or at least no longer significantly elevated from that baseline.

What Constitutes Robust Curing Criteria?

Moving an asset out of Stage 2 requires more than just a temporary improvement. Financial institutions need to establish clear, objective, and consistent criteria. These often blend quantitative and qualitative indicators, specific to the nature of the financial instrument and the circumstances that led to the Stage 2 classification.

One key element is an observation or 'probation' period. If an asset was classified into Stage 2 due to, say, a payment default or a breach of covenant, it's generally not sufficient for the customer to simply make one on-time payment. The institution would typically require a period of sustained good performance – perhaps 3 to 6 consecutive on-time payments, or a full quarter of compliance with all covenants – to demonstrate that the risk reduction is durable, not fleeting. This period ensures the reversal of the SICR is genuinely embedded.

Furthermore, the underlying reasons for the initial SICR must be adequately addressed and evidenced. For example, if a borrower entered Stage 2 due to a specific economic downturn impacting their industry, evidence of their improved financial health, diversification, or a broader industry recovery would be critical. Similarly, a positive change in the borrower's internal credit rating, confirmed by updated financial analysis, would be a strong indicator.

It's also crucial to consider the cumulative evidence. While a specific trigger might have moved an asset into Stage 2, the decision to move it back to Stage 1 should reflect an overall assessment of the asset's credit risk. This includes factors such as an updated assessment of the borrower's capacity to meet contractual obligations, the value of any collateral, and forward-looking economic information.

Why Is This Important?

Getting the curing criteria right is not just about compliance; it has tangible impacts. Misclassifying an asset in Stage 2 when it should be in Stage 1 leads to an overstatement of ECL, impacting profitability and potentially capital. Conversely, moving an asset back prematurely could understate risk. Robust curing criteria ensure that the reported ECL accurately reflects the underlying credit risk, providing a true and fair view of the institution's financial health.

In summary, while the journey into Stage 2 signifies increased credit risk, the path back to Stage 1 requires careful navigation. Robust, evidence-based curing criteria are essential to ensure that any deemed improvement in credit risk is genuinely sustained and that the asset's credit risk profile truly no longer represents a significant increase since its initial recognition. This precision is fundamental to the integrity of IFRS 9 ECL reporting.